Samsung Biologics to Spin Off Biosimilars UnitSamsung BiologicsSamsung Biologics plans to spin off its biosimilars subsidiary, Samsung Bioepis, by October 2025 to address conflict-of-interest concerns and enhance investor value, while continuing strong growth in its CDMO business.
Samsung Biologics 2024 Q4 Financial ReportFinancial statementsSamsung Biologics reports record-high revenue and orders for 2024, driven by success at Plant 4. The company secured its largest-ever contract, solidifying its position as a top global CDMO partner.
Samsung Biologics Hits $1.537B Revenue in Q2 2024Samsung BiologicsSamsung Biologics reported impressive Q2 2024 results with revenue of 1.16 trillion won and operating profit up 71.4%. The company secured $13 billion in orders, reflecting strong growth. Investments in ADC and biosimilars bolster their future prospects.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
